Re: 10-q ....
in response to
by
Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.
Message: Re: 10-q ....
The exact same language was in the previous report for the quarterly period ended August 31, 2010 filed in October, so it was reported.
FWIW, in the report period ended Feb 28, 2010, there was this language:
On August 17, 2009, the management committee of PDS resolved to pay TPL $500,000 per quarter beginning on June 1, 2009 and continuing through May 31, 2010 relating to TPL’s special work and effort regarding the MMP litigation and U.S. Patent Office re-examinations. In the event that PDS has insufficient funds to make such payments, we are required to advance half of the quarterly amount to PDS. Our advance to PDS will be without interest and must be repaid to us no later than May 31, 2010. In August 2009, TPL received two $500,000 payments from PDS pursuant to this agreement, the first of which is in dispute. At November 30, 2009, $500,000 was accrued by PDS pursuant to this agreement and funded to TPL by PDS in December 2009. At February 28, 2010 $500,000 was accrued by PDS pursuant to this agreement. These amounts are included in the legal and third-party expert fees, other related third-party costs and expenses, and certain internally generated costs listed above. As of the date of this filing, we have not advanced any funds to PDS under this resolution and do not anticipate any advances to PDS through May 31, 2010, the termination date of this resolution.
Fool PTSC once...
Loading...
Loading...
5
Jan 18, 2011 05:19PM
4
Jan 18, 2011 05:38PM
1
Jan 18, 2011 06:38PM
1
Jan 19, 2011 02:37AM
Jan 19, 2011 09:16AM
2
Jan 19, 2011 10:28AM
Jan 19, 2011 11:18AM
2
Jan 19, 2011 12:30PM
New Message
Please
login
to post a reply